OncoDNA SA

DUBLIN--( BUSINESS WIRE )--The "Worldwide Market for Liquid Biopsy, 6th Edition" report has been added to ResearchAndMarkets.com's offering. Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods. The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6th Edition provides an in-depth assessment of the market opportunity from 2023 to 2028. It covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types. Key applications of liquid biopsy testing in clinical oncology include: 1. Early Detection and Diagnosis/Screening: Identifying cancer at an early stage. 2. Alternative Testing Method: When tissue biopsy is challenging or impossible. When the primary site of metastatic disease is unknown. 3. Therapy Personalization and Monitoring: Molecular characterization to select optimal therapy. Monitoring treatment efficacy and adjusting therapy in case of resistance. 4. Disease Monitoring: Observing disease progression, tumor evolution, residual disease. Early detection of recurrence. 5. Prognosis of Disease: Assessing the likely course and outcome of the disease. Key Market Segments: By Region: North America Europe Asia Rest of World By Type of Liquid Biopsy: CTC-based Liquid Biopsy ctDNA-based Liquid Biopsy EV and Exosome-based Liquid Biopsy Multi-Analyte-based Liquid Biopsy Other Analytes Liquid Biopsy By Type of Cancer: Breast Lung Colorectal Ovarian Prostate Pan-Cancer Other Cancers R&D and Selected Tests: Selected ctDNA-based Liquid Biopsy Tests in Development Selected CTC-based Liquid Biopsy Tests in 2023 Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023 The growing acceptance of liquid biopsy, even during the COVID-19 pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth. Key Topics Covered: Chapter One: Executive Summary Liquid Biopsy Technologies Industry Structure Liquid Biopsy Market Revenues and Forecast Chapter Two: Liquid Biopsy Technologies Current Major Liquid Biopsy Technologies Chapter Three: Circulating Tumor DNA (Ctdna) Liquid Biopsy Advantages and Limitations of Ctdna in Liquid Biopsy Current Ctdna-based Liquid Biopsy Tests Biocartis Biodesix Cellmax Life Circulogene Diacarta Foundation Medicine (Roche) Guardant Health Inivata (Neogenomics) Lunglife AI Myriad Genetics Neogenomics Oncodna Personal Genomic Diagnostics (Labcorp) Qiagen Resolution Biosciences (Exact Sciences) Roche Diagnostics Sysmex-Inostics Tempus Ctdna-based Liquid Biopsy Tests in Development Exact Sciences Freenome Grail Chapter Four: Circulating Tumor Cells (Ctcs) Liquid Biopsy Challenges in the Development of Ctc-based Liquid Biopsy Tests Ctc-based Liquid Biopsy Tests Adaptive Biotechnologies Angle Cellmax Life Epic Sciences Gilupi Lunglife AI Menarini-Silicon Biosystems Qiagen Selected Ctc-based Liquid Biopsy Tests in Development Epic Sciences Liquid Biotech USA Chapter Five: Extracellular Vesicles and Other Liquid Biopsy Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analysts Aspira Women's Health (Formerly Vermillion) Biodesix Exosome Diagnostics Hologic Mdxhealth Extracellular Vesicle/Other Analyst-based Liquid Biopsy Tests in Development Circulogene Oncocyte Resolution Biosciences (Exact Sciences) Volitionrx Chapter Six: Multi-Analyst Liquid Biopsy Tests Liquid Biopsy Tests Based on Multiple Analysts Biodesix Foundation Medicine (Roche) Lunglife AI Neogenomics Oncodna Multiple Analyst-based Liquid Biopsy Tests in Development Exact Sciences Freenome Grail Lunglife AI Chapter Seven: Liquid Biopsy Tests for Research Use Only Liquid Biopsy Tests for Research Use Only Agena Bioscience Diacarta Exosome Diagnostics Guardant Health Natera Qiagen Chapter Eight: Liquid Biopsy Industry Analysis Tiers of Competition Competitive Factors Significant Market Trends Personalized Medicine Increasing Global Life Expectancy New Liquid Biopsy Products Increasing Accessibility of Genetic Testing Regulatory Hurdles Third-Party Payor Coverage Demonstrated Clinical Utility Incidence Rates of Specific Cancers Competitors No Longer in the Liquid Biopsy Market Chapter Nine: Liquid Biopsy Market Market Overview Market Forecast Chapter Ten: Market by Analyst Circulating Tumor DNA Circulating Tumor Cells Extracellular Vesicles and Other Analysts Chapter Eleven: Market by Application Therapy Guidance and Monitoring Diagnosis/Screening Disease Prognosis Chapter Twelve: Market by Cancer Type Breast Cancer Colorectal Cancer Lung Cancer Ovarian Cancer Prostate Cancer Other Cancers Pan-Cancer Tests Chapter Thirteen: Company Profiles Adaptive Biotechnologies Agena Bioscience, Inc. Angle, PLC Aspira Women's Health Biocartis Group Nv Biocept, Inc. (closed) Biodesix Cellmax Life Circulogene Diacarta, Inc. Epic Sciences Epigenomics AG (closed) Exact Sciences Exosome Diagnostics, Inc. Foundation Medicine, Inc. (Roche) Freenome, Inc. Gilupi Gmbh Grail (Illumina) Guardant Health, Inc. Hologic Lunglife AI (Formerly Cynvenio Biosystems) Menarini-Silicon Biosystems, SPA Myriad Genetics, Inc. Natera, Inc. Neogenomics Laboratories, Inc. Oncocyte Corporation Oncodna S.A. Personal Genome Diagnostics Qiagen N.V. Cell-Free DNA Technologies Ctc Technologies Exosome And Mirna Technologies Resolution Biosciences (Agilent) Roche Diagnostics Sysmex-Inostics, Inc. Tempus Volitionrx For more information about this report visit https://www.researchandmarkets.com/r/7c9qdk About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

LIÈGE, Belgium & GRENOBLE, France--( BUSINESS WIRE )--PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia. This is the result of a call for proposals on R&D projects in the field of Advanced Therapy Medicinal Products (ATMP). Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma. The total budget is €12.5M ($13.7M). The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology. Targeting unique neoantigens in each colorectal cancer patient, PDC*neo+ represents a groundbreaking approach in cancer immunotherapy. Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy. PDC*neo+ is designed as an adjuvant treatment to prevent relapses in high-risk patients with stages II, III and certain stage IV CRCs. Its action post-chemotherapy potentially makes it a pioneering treatment in CRC. This project is a collaborative effort involving several key partners. OncoDNA contributes its expertise in personalized medicine and liquid biopsies, focusing on neoantigen identification and circulating tumor DNA analysis. salamanderU is developing a compact isolator for decentralized vaccine production to bring manufacturing closer to the clinical centers. Academic centers UCLouvain – IREC (Institut de Recherche Expérimentale et Clinique)/MIRO (Molecular Imaging, Radiotherapy and Oncology) and ULB-BCTL (Breast Cancer Translational Research Laboratory) offer essential support in translational research and clinical trial execution. The main goal of the project is to confirm the clinical feasibility and safety of PDC*neo+ in a phase I trial. This initiative is expected to have a significant impact on CRC patient care, alongside broader economic and societal benefits. Over its three-year duration, across all partners, it is estimated to create or maintain around 34 full-time jobs. “We are very happy that our project has been selected by the Walloon region. The subsidies and collaborative effort of the partners in the consortium will speed-up the launch of a first phase I clinical trial with PDC*neo+, the personalized vaccine based on PDC*line cells loaded with neoantigens to treat CRC patients, positioning our technology in the very promising field of neoantigen-based cancer vaccines,” said Eric Halioua, CEO of PDC*line Pharma. “We are very thrilled to be part of this innovative project and clinical trial. It acknowledges our recent proficiency in the discovery of neoantigens and our robust experience in liquid biopsy monitoring by detection of circulating tumor DNA (ctDNA)," said Jean-Pol Detiffe, founder and chief strategy and innovation officer at OncoDNA. “We are very enthusiastic about participating in this collaborative project and bringing the production of PDC*Neo+ closer to the patient. Through this project, salamanderU strengthens its position as a designer and manufacturer of innovative isolators for the manufacture of ATMP,” said Claude Dedry, CEO of salamanderU. “We are very pleased and motivated to take part in this exciting and collaborative project. With our expertise, we will contribute to characterizing the immunogenicity of colorectal cancers and to the development and recruitment of patients for this clinical trial,” said Marc Van den Eynde and Jean-Pascal Machiels, oncologists at UCLouvain (Cliniques universitaires St-Luc). “We are delighted to be involved in this interesting collaborative project. Leveraging our expertise in various ‘omics’ technologies, such as single-cell RNA sequencing and spatial transcriptomics, we will delve into the tumor microenvironment of colorectal cancers. Our objective is to develop predictive biomarkers for vaccine response and actively contribute to patient recruitment for the clinical trial," said Christos Sotiriou, head of the BCTL at ULB and Francesco Sclafani, gastrointestinal oncologist and clinical researcher at Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB) and Bordet Cancer Research Laboratory. About PDC*line Pharma Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma is now focused on the development of PDC*lung01, its candidate for Non-Small-Cell Lung Cancer (NSCLC), currently in phase I/II trials, and PDC*neo with neoantigens, in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €61M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted the LG Chem Life Sciences company an exclusive license in South Korea and an exclusive option in other Asian countries for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia. www.pdc-line-pharma.com About OncoDNA OncoDNA is a leading genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers, and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France. OncoDNA employs over 115 employees across 9 countries, works with an international network of 35 distributors and collaborates with European-based accredited laboratories. OncoDNA is keen to meet laboratory partners and oncologists who would like to benefit from our expertise and work in partnership with us for the benefit of oncologists and their patients. Visit www.oncodna.com About salamanderU salamanderU is a technology company made up of a multidisciplinary team of business experts in the life sciences, pharmaceutical engineering and IT industries. We enhance our clients’ competitive advantage by increasing the robustness and the efficiency of their operational pharmaceutical processes. salamanderU develops and commercializes both technical and digital solutions: technical with acrylic resin isolators, and digital with voice-controlled electronic batch record and manufacturing execution system software. www.salamanderu.com About UCLouvain IREC/MIRO and Cliniques universitaires Saint-Luc UCLouvain is one of the most important universities in Belgium. The IREC-MIRO-Oncology laboratory (UCLouvain) and the Cancer and Hematology Roi Albert II Institute at Cliniques universitaires Saint-Luc have expertise in clinical, translational and fundamental research in oncology. Through the conduct of several academic studies, we have characterized the tumor microenvironment of several cancers and investigated the effectiveness of different combinations of targeted and immune therapies. Our phase 1 research unit is internationally recognized in the investigation of innovative therapies such as novel immune and genetic treatments. www.uclouvain.be About IJB The Institut Jules Bordet (IJB) is the only Comprehensive Cancer Centre in Belgium and is part of the Hopital Universitaire de Bruxelles (HUB) and of the Université Libre de Bruxelles (ULB). The strength of IJB is built upon its integration of three missions: excellence of care, innovative research and a high level of education. The Institute has participated in the creation of several international networks, including the European Organization for Research and Treatment of Cancer (EORTC), the Breast International Group (BIG), Accelerating Oncology Drug Development and Innovative Strategies in Clinical Trials (Oncodistinct) and the Organization of European Cancer Institutes (OECI). The Breast Cancer Translational Research Laboratory (BCTL), headed by Prof. Sotiriou, is an academic laboratory at the ULB faculty of medicine located within the Institut Jules Bordet. The main research focus of BCTL consists of improving the molecular understanding of breast cancer biology, disease dissemination and progression using state-of-the art ‘omics’ technologies as well as identifying novel prognostic and predictive biomarkers. The ultimate goal of this laboratory is to accelerate the translation into the clinic of basic science discoveries dedicated to breast cancer. www.bordet.be

DUBLIN, Dec. 7, 2022 /PRNewswire/ -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to ResearchAndMarkets.com's offering. The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? The publisher looks at Price and Volume Outlooks by type of cancer. This report provides detailed analysis. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test. Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring. Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. Key Topics Covered: 1 Market Guides 2 Introduction and Market Definition 3 Market Overview 3.1 Players in a Dynamic Market 3.1.1 Academic Research Lab 3.1.2 Diagnostic Test Developer 3.1.3 Instrumentation Supplier 3.1.4 Chemical/Reagent Supplier 3.1.5 Pathology Supplier 3.1.6 Independent Clinical Laboratory 3.1.7 Public National/regional Laboratory 3.1.8 Hospital Laboratory 3.1.9 Physicians Office Lab (POLS) 3.1.10 Audit Body 3.1.11 Certification Body 3.2 Using Biopsies 3.2.1 Cancer 3.2.2 Precancerous conditions 3.2.3 Inflammatory conditions 3.3 Biopsy Sites 3.4 The Situation Today - Biopsy Analysis 3.5 Evidence of Cancer - Liquid Biopsy Technology 3.5.1 The Big Picture on Liquid Biopsy Technology 3.5.2 The Role of CTCs 3.5.3 Application of CTCs 3.5.4 CellSearch Detection- Ultimate Sensitivity 3.5.5 Epic Sciences Detection- Imaging Takes the Lead 3.5.6 Maintrac Detection - The Microscope 3.5.7 Other Methods 3.5.8 ctDNA Role 3.5.9 ctDNA Applications 3.5.10 Exosomes and Micro Vesicles - New Kid on the Block 3.5.11 The Multiple Play 3.6 Cancer Treatment Protocol Under Siege 3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics 3.6.2 The Cancer Screening Market Opportunity 3.6.2.1 GRAIL - What Is It? 3.6.3 Cancer Management vs. Diagnosis 3.6.3.1 The Role of Risk Assessment 3.6.3.2 Managing Therapy 3.6.3.3 Monitoring Disease - What Is It? 3.6.4 Phases of Adoption - Looking into The Future 3.6.5 The Promise of Liquid Biopsy 3.7 Structure of Industry Plays a Part 3.7.1 Hospital Testing Share 3.7.2 Economies of Scale 3.7.2.1 Hospital vs. Central Lab 3.7.3 Physician Office Lab's 3.7.4 Physician's and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Non-Invasive Game Changer 4.1.2 Lower Cost 4.1.3 Greater Accuracy 4.1.4 Wide Range of Potential Uses 4.1.5 Aging Population 4.2 Factors Limiting Growth 4.2.1 Lower prices 4.2.2 Lack of Standards 4.2.3 Protocol Resistance 4.2.4 Initial Adoption Cost 4.2.5 Conclusion 4.3 Instrumentation and Automation 4.3.1 Instruments Key to Market Share 4.3.2 Bioinformatics Plays a Role 4.4 Diagnostic Technology Development 4.4.1 Next Generation Sequencing Fuels a Revolution 4.4.2 Impact of NGS on pricing 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 4.4.4 CGES Testing, A Brave New World 4.4.5 Biochips/Giant magneto resistance based assay 5 Liquid Biopsy Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 PamGene Expanding Liquid Biopsy Assays 5.3 Liquid Biopsy Firm Hedera Dx Raises €14M 5.4 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx 5.5 Precision Oncology Dx Access Varies Widely in Europe 5.6 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic 5.7 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy 5.8 BillionToOne Launches First Liquid Biopsy Products 5.9 Dxcover Advances Multicancer Detection Platform 5.10 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test 5.11 Illumina Sues Guardant Health Over Patents 5.12 Invitae to Expand Cancer Testing Portfolio 5.13 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies 5.14 IVBH Bio Takes Aim at With Liquid Biopsy Incubator 5.15 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership 5.16 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech 5.17 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy 5.18 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform 5.19 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding 5.20 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition 5.21 Bio-Techne to Acquire Asuragen for up to $320M 5.22 Personalis Broadens Liquid Biopsy Offering 5.23 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition 5.24 Delfi Diagnostics Plans Multi-Cancer Screening Test 5.25 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response 5.26 Liquid Biopsy NGS Panels - Diverse Test Claims 5.27 CMS Colon Cancer Screening Memo Bodes Well for Assays 5.28 Natera Liquid Biopsy Test Coverage to Expand 5.29 Freenome Closes Financing to Support Early Cancer Detection Trial 5.30 C$2.6M Liquid Biopsy Initiative 5.31 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy 5.32 Liquid Biopsy Shows Promise as Screen for Cancers 5.33 Inivata launches RaDaRT for the detection of residual disease and recurrence 5.34 Liquid Biopsy Assay Detects 50+ Types of Cancer 5.35 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy 6 Profiles of Key Players 6.1 Abbott Laboratories 6.2 AccuraGen Inc. 6.3 Acuamark Diagnostics 6.4 Admera Health, LLC 6.5 Agilent/Dako 6.6 Amoy Diagnostics Co., Ltd 6.7 Anchor Dx 6.8 ANGLE plc 6.9 Applied DNA Sciences 6.10 ARUP Laboratories 6.11 AVIVA Systems Biology 6.12 Baylor Miraca Genetics Laboratories 6.13 Beckman Coulter Diagnostics 6.14 Becton, Dickinson and Company 6.15 BGI Genomics Co. Ltd 6.16 Bioarray Genetics 6.17 Biocartis 6.18 Biocept, Inc. 6.19 Biodesix Inc. 6.20 BioFluidica 6.21 bioMerieux Diagnostics 6.22 Bioneer Corporation 6.23 Bio-Rad Laboratories, Inc 6.24 Bio-Techne 6.25 Bioview 6.26 Bolidics 6.27 Boreal Genomics 6.28 Burning Rock 6.29 Cardiff Oncology 6.30 Caris Molecular Diagnostics 6.31 CellCarta 6.32 CellMax Life 6.33 Cepheid (Danaher) 6.34 Circulogene 6.35 Cizzle Biotech 6.36 Clinical Genomics 6.37 Cytolumina Technologies Corp 6.38 Datar Cancer Genetics Limited 6.39 Diagnologix LLC 6.40 Dxcover 6.41 Enzo Biochem 6.42 Epic Sciences 6.43 Epigenomics AG 6.44 Eurofins Scientific 6.45 Exact Sciences 6.46 Fluxion Biosciences 6.47 Freenome 6.48 Fyr Diagnostics 6.49 GeneFirst Ltd. 6.50 Genetron Holdings 6.51 GILUPI Nanomedizin 6.52 Guardant Health 6.53 HansaBiomed 6.54 HeiScreen 6.55 Helomics 6.56 iCellate 6.57 ICON PLC 6.58 Illumina 6.59 Incell Dx 6.60 Inivata 6.61 INOVIQ 6.62 Integrated Diagnostics 6.63 Invitae Corporation 6.64 Janssen Diagnostics 6.65 Lunglife AI Inc 6.66 MDNA Life SCIENCES, Inc 6.67 MDx Health 6.68 Menarini Silicon Biosystems 6.69 Mesa Laboratories, Inc 6.70 Millipore Sigma 6.71 Miltenyi Biotec 6.72 miR Scientific 6.73 Myriad Genetics/Myriad RBM 6.74 NantHealth, Inc 6.75 Natera 6.76 NeoGenomics 6.77 Novogene Bioinformatics Technology Co., Ltd 6.78 On-Chip Biotechnologies 6.79 Oncocyte 6.80 OncoDNA 6.81 Oxford Nanopore Technologies 6.82 PamGene 6.83 Panagene 6.84 Perkin Elmer 6.85 Personal Genome Diagnostics 6.86 Precision Medicine Group 6.87 PrecisionMed 6.88 Predicine 6.89 Promega 6.90 Qiagen 6.91 Rarecells SAS 6.92 RareCyte 6.93 Roche Molecular Diagnostics 6.94 Screencell 6.95 Siemens Healthineers 6.96 simfo GmbH 6.97 Singlera Genomics Inc 6.98 Standard BioTools 6.99 Sysmex Inostics 6.100 Tempus Labs, Inc 6.101 Thermo Fisher Scientific Inc 6.102 Todos Medical 6.103 Veracyte 6.104 Volition 6.105 Vortex Biosciences 7 The Global Market for Liquid Biopsy Diagnostics 7.1 Global Market Overview by Country 7.2 Global Market by Cancer - Overview 7.3 Global Market by Usage - Overview 7.4 Global Market by Place - Overview 7.4.1 Table - Global Market by Place 7.5 Global Market by Marker - Overview 7.6 Global Market by Product - Overview 8 Global Liquid Biopsy Diagnostic Markets - By Cancer 8.1 Breast 8.2 Colorectal 8.3 Cervical 8.4 Lung 8.5 Prostate 8.6 Other 9 Global Liquid Biopsy Diagnostic Markets - by Usage 9.1 Screening 9.2 Chart - Screening Growth 9.3 Diagnostic 9.4 Therapy 9.5 Monitor 10 Global Liquid Biopsy Diagnostic Markets - by Place 10.1 Hospital Lab 10.2 Lab Service 10.3 Lab Outpatient 10.4 Other Lab 11 Global Liquid Biopsy Diagnostic Markets - by Marker 11.1 Circulating Tumor Cell 11.2 Cell Free DNA 11.3 Vesicle 11.4 Other Marker 12 Global Liquid Biopsy Diagnostic Markets - by Product 12.1 Kits 12.2 Instruments 12.3 Service 13 Appendices For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets